Black­stone in­vests $400M in one of Chi­na's fast-grow­ing phar­ma com­pa­nies; CVS sets up an ICER-based for­mu­la­ry

→ The Black­stone Group is in­vest­ing $400 mil­lion in YiChang HEC ChangJiang Phar­ma­ceu­ti­cal. The big pri­vate eq­ui­ty play­er is back­ing the com­pa­ny via con­vert­ible bonds …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER